Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 study.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
A Phase 1 Study to Assess the Effect of Fruquintinib on the Pharmacokinetics of P-gp and BCRP Substrates in Healthy Subjects.
Journal: Clinical and translational science
Published: August 21, 2025
Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan.
Journal: International journal of clinical oncology
Published: April 09, 2025
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 24, 2025
Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib.
Journal: Journal of clinical pharmacology
Published: December 20, 2024
Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: November 08, 2024
Assessment of Food Effect and pH-Dependent Drug-Drug Interactions of Fruquintinib in Healthy Subjects.
Journal: Clinical and translational science
Published: November 08, 2024
Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 25, 2024
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States.
Journal: Investigational new drugs
Published: July 25, 2023
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Journal: Lancet (London, England)
Published: December 15, 2022
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.
Journal: Future oncology (London, England)
Published: May 17, 2021
Last Updated: 09/26/2026